azacitidine has been researched along with Adverse Drug Event in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM | 1 |
| Fujiwara, M; Muroi, N; Shimizu, T; Uchida, M; Uesawa, Y; Yamaoka, K | 1 |
| Alsaadi, D; Clesham, K; Low, L; Rowan, F; Zubairu, M | 1 |
| Adès, L; Chermat, F; Fenaux, P; Giagounidis, A; Gloaguen, S; Götze, KS; Krönke, J; Kubasch, AS; Middeke, JM; Mies, A; Oelschlägel, U; Platzbecker, U; Puttrich, M; Schlenk, RF; Schulze, F; Sockel, K; Stasik, S; Thiede, C; Weigt, C; William, D | 1 |
| Coleman, E; Cowper, S; Gore, S; Leventhal, J; Panse, G; Prebet, T | 1 |
| Beach, CL; Döhner, H; Dombret, H; Dougherty, D; Gambini, D; Minden, MD; Seymour, JF; Stone, R; Weaver, J | 1 |
| Garcia-Manero, G; Kantarjian, H; Sharma, S; Stoltz, ML; Ward, MR | 1 |
| Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R | 1 |
| Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA | 1 |
| Dressman, HK; Gollob, JA; Issa, JP; Jelinek, J; Moran, K; Peterson, BL; Richmond, T; Sciambi, CJ; Thoreson, M | 1 |
| Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H | 1 |
7 trial(s) available for azacitidine and Adverse Drug Event
| Article | Year |
|---|---|
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines | 2021 |
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Interleukin-3 Receptor alpha Subunit; Male; Myelodysplastic Syndromes; Prognosis; Survival Rate | 2020 |
A pilot pharmacokinetic study of oral azacitidine.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Pharmacokinetics; Pilot Projects | 2008 |
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Gemtuzumab; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Remission Induction; Risk Assessment; Survival Analysis | 2008 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide | 2013 |
Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Renal Cell; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fetal Hemoglobin; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Injections, Intravenous; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Predictive Value of Tests; Treatment Outcome | 2006 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA Methylation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation; Histones; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; Tretinoin; Valproic Acid | 2007 |
6 other study(ies) available for azacitidine and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Topics: Azacitidine; Drug-Related Side Effects and Adverse Reactions; East Asian People; Heart Failure; Humans; Pharmacovigilance | 2023 |
Azacitidine as a rare cause of reactive arthritis in a patient with acute myeloid leukemia.
Topics: Aged; Arthritis, Reactive; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies | 2023 |
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease.
Topics: Aged; Antineoplastic Agents; Azacitidine; Diagnosis, Differential; DNA; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Male; Methyltransferases; Middle Aged; Neutrophils; Panniculitis; Prednisone; Skin Diseases; Treatment Outcome | 2019 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Female; Health Resources; Hospitalization; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Mortality | 2017 |